News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MTTI Announces That Response Of Colorectal Cancer To Treatment Can Be Detected As Early As One Day After A Single Administration Of Drug



12/1/2016 11:06:27 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

WEST CHESTER, Pa.--(BUSINESS WIRE)--Molecular Targeting Technologies, Inc. (MTTI) announces that response of colorectal cancer to treatment can be detected with their innovative diagnostic agent (Tc-99m duramycin-TumorVue™) as early as one day after a single administration of drug. Results from this preclinical study were published online*.

Although imaging agents such as 18F-FDG show great promise as biomarkers for early response to targeted cancer therapy, conflicting results are reported after immunotherapy. If our preclinical findings can be confirmed in patients, TumorVue™ has the potential to fill this gap since it does not seem to be hampered by the presence or absence of an inflammatory response,” said Professor Sigrid Stroobants of the Antwerp University Hospital (UZA).

Detection of early treatment response will allow for improved management of cancer patients in the clinic. This study demonstrated that TumorVue™ enables readout of tumor response to targeted therapy as early as one day after start of treatment,” said Dr. Leonie Wyffels at the University of Antwerp’s Molecular Imaging Center Antwerp (UAntwerp-MICA). “The superiority of TumorVue™ over 18F-FDG for early detection of treatment response in colorectal tumors is exciting.”

Chris Pak, President and CEO of MTTI said, “We are encouraged by the results of TumorVue™ for detection of treatment response to targeted therapy as early as one day. Our goal is to translate these findings into patients to differentiate responders from non-responders. This innovative agent will be a powerful tool for personalized medicine where cancer patients will be spared the toxicity of ineffective therapy.”

UAntwerp-MICA was founded in 2010 as a joint effort by the UAntwerp and the UZA and has become one of the front runners in translational from bench to patient. UAntwerp is not an island: we build bridges to secondary education, to industry and, by extension, to society as a whole. With over 5,000 members of staff, UA is one of the most important employers in Antwerp, Flanders’ largest city. More information: www.uantwerp.be

MTTI is a privately held biotechnology company focused on the development of diagnostic technologies. More information: www.mtarget.com.

*J Nucl Med. 2016 as doi:10.2967/jnumed.116.182014. 99mTc-duramycin SPECT imaging of early tumor response to targeted therapy: a comparison with 18F-FDG PET.

Contacts

MTTI
Chris Pak, 610-738-7938
cpak@mtarget.com
or
UAntwerp-MICA
Peter Demeyer
peter.demeyer@uantwerpen.be


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES